Dr. DeAngelo on Inotuzumab Ozogamicin for Relapsed/Refractory ALL


Daniel J. DeAngelo, MD, PhD, director of clinical and translational research, Adult Leukemia Institute (ALL), Dana-Farber Cancer Institute, discusses inotuzumab ozogamicin compared to standard chemotherapy in the INO-VATE study for patients with acute lymphoblastic leukemia (ALL).

Inotuzumab ozogamicin is an anti—CD22 antibody-drug conjugate. Over 90% of patients with B-cell ALL express CD-22 on their surface. Several phase I and II studies showed that inotuzumab ozogamicin had very high clinical activity/

In the phase III trial INO-VATE trial inotuzumab ozogamicin demonstrated a median PFS of 5.0 months (95% CI, 3.7-5.6) compared with 1.8 months (95% CI, 1.5-2.2) with standard chemotherapy (HR, 0.45; 97.5% CI, 0.34-0.61; P <.001)

The complete remission (CR) or CR with incomplete hematologic recovery (CRi) rate was 80.7% with inotuzumab ozogamicin (95% CI, 72.1-88.7) compared with 29.4% of those who received standard chemotherapy (95% CI, 21.0-38.8; P <.001).

Related Videos
Naval G. Daver, MD
Pasi A. Jänne, MD, PhD
Saad Z. Usmani, MD, MBA, FACP
J. Randolph (Randy) Hecht, MD
Alessandro Di Federico, MD
Qian (Janie) Qin, MD
Judy C. Boughey, MD
Tian Zhang, MD, MHS
Francisco J. Esteva, MD, PhD
Related Content